Skip to main content
. 2018 Dec 5;35(4):354–362. doi: 10.36141/svdld.v35i4.7061

Table 1.

General features (clinical and instrumental data) of the study population

Groups
PS ILD
N. of subjects 10 9
Age, years (mean±SD) 57±10 64±11
Sex F/M 4F/6M 3F/6M
Clinical diagnosis Sarcoidosis Interstitial lung diseases
FVC % (range; mean±SD) 71-98; 94.2±15.6 42-88; 63.8±28.8
DLCO % (range; mean±SD) 25-85; 66.7±17.5 34-75; 54.3±15
Recent infections 0/10 0/9
Probiotics assumption 0/10 0/9
Immunosuppressive therapy (N) 1/10 0/9
Corticosteroid therapy (N) 2/10 1/9

PS, pulmonary sarcoidosis patients; ILD, interstitial lung diseases; SD, standard deviation; F, female; M, male; FVC, forced vital capacity; DLCO, diffusing capacity of the lung carbon monoxide; N, number